Zydus Lifesciences (ZYDUSLIFE): Press Release

Press Release Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority

1 min read Zydus Lifesciences

Press Release

Press Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA".

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA".

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA".

Disclaimer

This article is for informational purposes only and is not investment advice. Verify all figures and announcements from official exchange filings and company disclosures before making decisions.

#Zydus Lifesciences Ltd #ZYDUSLIFE #Corporate announcement

Track Indian stocks with ZTOX AI

Get started free

Track Indian stocks with ZTOX AI

NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.

Insider Deals Alert
Volume Breakouts
Block Deal Notifications
Preferential Issue Alerts
Free ₹0
Basic ₹89/mo
Advanced ₹119/mo
No credit card required to start on the free plan.
Start Free Now